Purchase this article with an account.
Maria Pefkianaki, Vasilios Papastefanou, Richard Andrews, Victoria Cohen, Mandeep S Sagoo; Bevacizumab injections in patients with a choroidal neovascular membrane secondary to choroidal osteoma. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3097.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To present the outcomes of a series of patients with choroidal neovascular membrane (CNV) secondary to a choroidal osteoma.
In this retrospective series patients underwent complete clinical and imaging assessment (fundus photo, fluorescein angiography and optical coherence tomography) and were managed with intravitreal anti-VEGF injections. Visual acuity and central retinal thickness were recorded pre treatment and at the end of follow up period.
Six patients were included in this study. Of this, 4/6 had predominantly classic or classic and 2/6 patients had minimally classic or occult CNV. Treatment with intravitreal anti-VEGF was applied in all cases (1-3 injections of bevacizumab). Median follow up was 6 months (6-10 months). Visual acuity improved in all patients by 2-6 Snellen lines. CNV completely regressed in 4 cases and partially regressed in 2 cases. Central retinal thickness change ranged from -222 μm to +60 μm.
Intravitreal bevacizumab is an effective treatment modality in the management of vision threatening choroidal neovascular membrane secondary to choroidal osteoma
This PDF is available to Subscribers Only